초록 ▼

Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detec

Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell.

대표청구항 ▼

What is claimed is: 1. A cationic liposome, comprising: cationic lipids; and a taxane in a lipid bilayer of the liposome, wherein the liposome comprises substantially no taxane crystals, wherein the taxane does not substantially partition from the lipid bilayer, wherein said liposome comprises from

What is claimed is: 1. A cationic liposome, comprising: cationic lipids; and a taxane in a lipid bilayer of the liposome, wherein the liposome comprises substantially no taxane crystals, wherein the taxane does not substantially partition from the lipid bilayer, wherein said liposome comprises from about 30 mole % to about 98 mole % cationic lipid, and from about 2 mole % to about 20 mole % taxane, and wherein the liposome has a diameter of from about 100 nm to about 400 nm. 2. The cationic liposome of claim 1, further comprising a detectable label. 3. The cationic liposome of claim 1, further comprising a water-soluble taxane in an aqueous compartment of the liposome. 4. The cationic liposome of claim 1, wherein the taxane is a pharmaceutically acceptable derivative. 5. The cationic liposome of claim 1, wherein the taxane is paclitaxel. 6. The cationic liposome of claim 1, wherein the taxane is docetaxel. 7. The cationic liposome of claim 1, wherein the liposome comprises from about 2 mole % to about 15 mole % taxane, and from about 40 mole % to about 98 mole % cationic lipid. 8. The cationic liposome of claim 1, wherein said cationic liposome further comprises a neutral lipid. 9. The cationic liposome of claim 8, wherein the liposome comprises from about 1 mole % to about 80 mole % neutral lipid. 10. The cationic liposome of claim 1, wherein the taxane is present in an amount effective to inhibit angiogenesis, and wherein the liposome is stable between 4째 C. and 25째 C. for at least about 48 hours. 11. The cationic liposome of claim 8 or 9, wherein the neutral lipid is selected from the group consisting of a phosphatidylcholine (PC), a phosphatidylethanolamine (PE), and a mixture of a PC and a PE. 12. The cationic liposome of claim 8 or 9, wherein the liposome comprises DOTAP, egg phosphatidyl choline, and paclitaxel in a 50:48:2 molar ratio. 13. The cationic liposome of claim 8 or 9, wherein the liposome comprises DOTAP, DOPC, and paclitaxel in a 50:47:3 molar ratio. 14. The cationic liposome of claim 8 or 9, wherein the liposome comprises DOTAP, DOPE, and paclitaxel in a 50:47:3 molar ratio. 15. The cationic liposome of claim 8 or 9, wherein the liposome comprises DOTAP, MOPC, and paclitaxel in a 50:47:3 molar ratio. 16. A method of selectively affecting angiogenic endothelial cells, comprising the steps of: administering to a mammal a liposomal composition comprising a liposome according to claim 1, wherein the composition has greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells; and allowing the composition to associate with angiogenic endothelial cells of an angiogenic blood vessel for a time and in a manner such that the composition enters the angiogenic endothelial cells. 17. The method of claim 16, wherein the composition is administered by injection into the circulatory system and further wherein the composition has, in blood, two-fold or greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells. 18. The method of claim 16, wherein affinity is measured on an angiogenic endothelial cell to non-angiogenic endothelial cell basis. 19. The method of claim 18, wherein affinity is measured ex vivo. 20. The method of claim 16, wherein the injected composition has, in blood, ten-fold or greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells and wherein the composition is injected intravenously. 21. The method of claim 16, wherein taxane is selected from the group consisting of paclitaxel, docetaxel, a 10-desacetyl analog of paclitaxel, a 3'N-desbenzoyl-3'N-t-butoxycarbonyl analog of paclitaxel, a galactose or mannose derivative of a taxane, a piperazino derivative of a taxane, a 6-thio or a sulfonamide derivative of a taxane, and a taxane attached to a hydrophobic moiety. 22. The method of claim 16, wherein said taxane is paclitaxel. 23. The method of claim 16, wherein the angiogenic endothelial cells are associated with a tumor. 24. A cationic liposome, comprising: a cationic lipid; and a taxane in an aqueous compartment of the liposome, wherein the liposome comprises substantially no taxane crystals, wherein the taxane does not substantially partition from the aqueous compartment, wherein said liposome comprises from about 30 mole % to about 98 mole % cationic lipid and from about 2 mole % to about 20 mole % taxane, and wherein the liposome has a diameter of about 100 nm to about 400 nm. 25. The cationic liposome of claim 1, wherein the liposome has a diameter of about 100 nm to about 200 nm. 26. The cationic liposome of claim 1, wherein the liposome has a diameter of about 200 nm to about 300 nm. 27. The cationic liposome of claim 1, wherein the liposome has a diameter of about 100 nm to about 300 nm. 28. The cationic liposome of claim 1, wherein the liposome has a diameter of about 200 nm to about 400 nm. 29. A method of reducing an atherosclerotic plaque, comprising: administering to a mammal a composition comprising a liposome according to claim 1, wherein the composition has greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells; and allowing the composition to associate with angiogenic endothelial cells of an angiogenic blood vessel for a time and in a manner such that the composition enters the angiogenic endothelial cells, wherein reduction of angiogenesis results in reduction of atherosclerotic plaque formation. 30. The method of claim 29, wherein the composition is formulated for administration by injection into the circulatory system and further wherein the composition has, in blood, two-fold or greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells. 31. The method of claim 30, wherein the injected composition has, in blood, ten-fold or greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells. 32. A method of reducing atherosclerotic plaque formation in a patient, comprising the steps of: removing an atherosclerotic plaque from a circulatory vessel of the patient; and administering to the patient a therapeutically effective amount of a composition comprising a liposome according to claim 1, wherein the composition has greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells. 33. A method of inhibiting angiogenesis associated with a tumor comprising: administering to a mammal a composition comprising a liposome according to claim 1, wherein the composition has greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells; and allowing the composition to target angiogenic endothelial cells of a tumor, in a manner such that the composition enters the angiogenic endothelial cells and inhibits angiogenesis of the tumor. 34. The method of claim 33, wherein the composition is administered by injection into the circulatory system and further wherein the composition has, in blood, two-fold or greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells. 35. The method of claim 34, wherein the composition has, in blood, ten-fold or greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells. 36. A method of treating a mammal suffering from cancer comprising: administering to the mammal, a composition comprising a liposome according to claim 1, wherein the composition has greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells; and allowing the composition to target angiogenic endothelial cells associated with a tumor, in a manner such that the composition enters the angiogenic endothelial cells, inhibits angiogenesis of the tumor, and treats the mammal. 37. The method of claim 36, wherein the composition is administered by injection into the circulatory system and further wherein the composition has, in blood, two-fold or greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells. 38. The method of claim 37, wherein the composition has, in blood, ten-fold or greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells. 39. The cationic liposome of claim 8, wherein the liposome comprises from about 2 mole % to about 50 mole % neutral lipid. 40. The cationic liposome of claim 1, wherein the taxane does not substantially form crystals in a period of time of at least 24 hours at a temperature of from about 4째 C. and 25째 C. 41. The cationic liposome of claim 24, wherein the taxane does not substantially form crystals in a period of time of at least 24 hours at a temperature of from about 4째 C. and 25째 C.